STRIDES PHARMA SCIENCE LIMITED — Board/Management Information 2020

Jan 8, 2020

January 8, 2020

The Manager Listing The Manager Listing BSE Limited The National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra-Kurla Complex Dalal Street, Mumbai – 400 001 Bandra (E) Mumbai - 400 051 Scrip code: 532531 Scrip code: STAR

Dear Sirs,

Sub: Intimation of Appointment of Chief Executive Officer & Managing Director of the Company

This is to inform you that the Board of Directors of the Company in their meeting held today have approved the following:

• 1. Appointment of Dr. R Ananthanarayanan (DIN: 02231540) as Chief Executive Officer & Managing Director of the Company effective January 9, 2020, for a period of 5 years, subject to approval of the Members of the Company. Further, he is also appointed as Key Managerial Personnel of the Company effective January 9, 2020.

Disclosure under Regulation 30 of the SEBI Listing Regulations for the said appointment is enclosed as Annexure .

• 1. Re-designation of Mr. Arun Kumar (DIN: 00084845) as Executive Director effective January 9, 2020.

Request you to kindly take the above on record.

Thanks & Regards,

For Strides Pharma Science Limited

==> picture [121 x 55] intentionally omitted <==

Manjula Ramamurthy Company Secretary

==> picture [89 x 87] intentionally omitted <==

Strides Pharma Science Limited (Formerly Strides Shasun Limited) CIN: L24230MH1990PLC057062 Corp Off : Strides House, Bilekahalli, Bannerghatta Road, Bangalore - 560 076, India Tel: +91 80 6784 0000 Fax: +91 80 6784 0700 Regd Off : 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942 info@strides.com; www.strides.com

Annexure

Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Appointment of Dr. R. Ananthanarayanan as Chief Executive Officer and Managing Director w.e.f. January 9, 2020

#	Particulars	Remarks
1.	Reason for change viz.,appointment or otherwise	Appointment
2.	Date of appointment and term ofappointment	Dr. R Ananthanarayanan is appointed for a period of 5 yearsw.e.f January 9, 2020, subject to approval of the Members of theCompany.
3.	Brief Profile	Dr. R Ananthanarayanan brings with him over three decades oftop pedigree global pharmaceutical experience across both thetechnical and commercial functions. Until recently, Ananth wasthe Global Chief Operating Officer at Cipla Limited, where hewas responsible for the company’s generics business inregulated markets and branded generics in emerging markets. Hewas also driving their API business, biosimilars, complex drug-device combinations, including 505(b)(2) products.Prior to Cipla, Ananth was the President & CEO of Global APIs,Biologics,& MedisGenericsB2Bdivisionat TevaPharmaceutical Industries Ltd in the US, managing multi-billionP&L responsibility. He has also held leadership roles at Dr.Reddy’s Laboratories, Piramal Healthcare (Formerly NicholasPiramal), Galpharm International, UK (Acquired by PerrigoGroup), and Zydus Cadila.Ananth is a Graduate in Pharmaceutical Sciences and earned hisPh.D. in Pharmaceutical Technology from the University ofMumbai, India. He has also been a member of the Board ofAdvisors at the School of Pharmacy and Health Sciences atFairleigh Dickinson University, New Jersey.
4.	Disclosure of relationshipsbetween directors	Dr. R. Ananthanarayanan is not related to any other Director ofthe Company.

---

Strides Pharma Science Limited (Formerly Strides Shasun Limited) CIN: L24230MH1990PLC057062 Corp Off : Strides House, Bilekahalli, Bannerghatta Road, Bangalore - 560 076, India Tel: +91 80 6784 0000 Fax: +91 80 6784 0700 Regd Off : 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942 info@strides.com; www.strides.com